Peter Nell

Peter Nell joins TreeFrog Therapeutics as Independent Board Member


Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell & gene therapy field over the past ten years and is currently building a new gene editing biotech company. He has worked for over 16 years at Bayer Healthcare, both in the US and Germany, moving from therapeutic research in chemistry (co-inventor of Letermovir and Neladenoson) to leadership positions in business development & licensing and strategic marketing. In 2016, he co-founded Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics developing CRISPR/Cas9-based gene therapies. Following Casebia’s acquisition by CRISPR Therapeutics in 2019, Peter joined “CRISPR platform” company Mammoth Biosciences as Chief Business Officer and Head of Therapeutics Strategy, initiating collaborations with Vertex and Bayer and supporting fundraising ($195m Series C/D) while the company grew from 20 to 150 employees.

Interview of Peter Nell, Independent Board Member, TreeFrog Therapeutics

“Peter is a great addition to our board. He brings an extensive experience in the construction of therapeutic alliances and deep knowledge of the cell & gene therapy ecosystem in the USA – two strategic areas for TreeFrog Therapeutics. And as we progress the C-Stem technology with the addition of gene editing competencies, his expertise in these technologies such as CRISPR will be invaluable” said Frederic Desdouits, CEO, TreeFrog Therapeutics.

“I am thrilled to have Peter join our team.  As we grow our company and capabilities, we intend to create a portfolio of in-house and partnered programs, and Peter is the perfect profile to help us achieve this goal. » Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics

“I feel very honored having been selected as an independent board member at TreeFrog Therapeutics as the company addresses an area of high need to create meaningful cell therapy approaches to combat severe diseases. Coming from Europe I am excited to see a biotech from France increasing their impact and personally being given the opportunity to contribute to this success story with my knowledge and experience,” said Peter Nell.

About TreeFrog Therapeutics

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem™ technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline in regenerative medicine and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-Stem™ and build strategic alliances with leading academic, biotech and industry players in the field of cell therapy.

Media Contact:

Pierre-Emmanuel Gaultier
+ 33 6 45 77 42 58